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Purpose: To investigate the molecular signaling pathway of Interferon gamma (IFNγ) contributing to angiogenesis in
retinal pigmented epithelial (RPE) cells and the role of Phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin
(mTOR) in this process.
Methods: Human adult and fetal RPE cells were used in this study. Real-time polymerase chain reaction was used to
detect human vascular endothelial growth factor (VEGF) mRNA expression. Thiazolyl blue tetrazolium bromide (MTT)
assay was used to detect cell viability. VEGF expression from cell supernatant was measured using enzyme-linked
immunosorbent assay (ELISA). Small interfering RNA (SiRNA) of signal transducers and activators of transcription 1
(stat1) and protein kinases B (akt) were transfected into ARPE-19 cells to directly study the roles of these molecules in
VEGF expression. Sodium dodecyl sulfate PAGE (SDS–PAGE) and western blot analysis were used to detect the
expression of signaling molecules.
Results: IFNγ promoted human VEGF expression in both adult and fetal RPE cells. The PI-3K/Akt/mTOR/p70 S6 kinase
pathway is required for IFNγ-induced VEGF expression in retinal cells. The mTOR inhibitor, rapamycin, along with the
SiRNA targeted to akt and the PI3K inhibitor, LY294002, decreased hVEGF secretion from RPE cells. Moreover,
IFNγ-induced hVEGF expression was not affected by SiRNA targeted to Stat1, implying that the classic Jak-Stat1 pathway
of IFNγ may not be involved in this process.
Conclusions: We provide evidence that IFNγ induces VEGF expression in human retinal pigment epithelial cells. Our
work emphasizes that the activation of the PI-3K/mTOR/translational pathway is important for IFNγ-mediated VEGF
expression in RPE cells. By elucidating molecular signaling involved in this process, our findings provide further
mechanistic insight into the successful clinical application of rapamycin therapy for choroidal neovascularization in age-
related macular degeneration (AMD) and uveitis.
Angiogenesis is the result of a net balance between the
activities  exerted  by  positive  and  negative  regulators  [1].
Mounting evidence strongly suggests that the immune system
plays an important role in angiogenesis. Pro-inflammatory
cytokines, such as Interferon gamma (IFNγ); interleukin-6
(IL-6); tumor necrosis factor alpha (TNFα); Interleukin 1 beta
(IL-1β) are the major cytokines in the pathogenesis of ocular
inflammatory  diseases.  Many  of  the  proinflammatory
cytokines are involved in inflammatory angiogenesis [2–5].
However, IFNγ is thought to be an anti-angiogenic cytokine,
due to its inhibitory effect on endothelial cell growth and
capillary formation [1,6–8].
The classic signaling events induced by IFNγ are through
the Janus kinase (Jak) pathway and the signal transducer and
activator of transcription 1 (Stat1) pathway. The cascade of
signal transduction is initiated upon the binding of dimeric
IFNγ to its receptor, followed by the activation of the receptor-
associated Jak1 and Jak2, which in turn phosphorylate Stat1.
Stat1 then translocates into the nucleus and functions as a
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transcription factor. Beyond the Jak/Stat1 pathway, IFNγ can
also activate the mitogen activated protein kinase (MAPK)
and Phosphoinositide 3-kinase (PI3K) pathways [9]. The roles
of these pathways in IFNγ-induced biologic effects, however,
have not been clearly defined.
We recently reported treating a patient with multifocal
choroiditis associated with choroidal neovasculization (CNV)
with rapamycin, an mammalian target of rapamycin (mTOR)
inhibitor [10]. CNV occurs in many intraocular inflammatory
diseases such as uveitis, age-related macular degeneration
(AMD), and others. Among them, AMD is the leading cause
of blindness in the United States for people over 60 years old.
In the wet, or exudative, AMD, choroidal blood vessels grow
through Bruch’s membrane into the subretinal space, causing
CNV, and resulting in accumulation of blood beneath the
retina. CNV is present in only 10% of patients with AMD, but
is responsible for 90% of cases with severe vision loss [11].
Vascular endothelial growth factor (VEGF) is known to play
an important role in this process. It has been associated with
choroidal  neovascular  membranes,  the  retinal  pigment
epithelium (RPE), and maculae with AMD [12]. Intraocular
delivery of anti-VEGF therapies is now widely accepted as a
treatment for the wet form of AMD. The pro-inflammatory
cytokine IFNγ plays an important role in the pathogenesis of
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184intraocular inflammatory disease. In the aqueous and vitreous
of uveitis patients, IFNγ can reach levels greater than 100 pg/
ml [13,14]. Mounting evidence supports the notion that AMD
may be an inflammation-driven disease [1,6–8]. Although
there  are  no  studies  showing  the  increased  expression  of
IFNγ in AMD patients, it has been reported that IFNγ induces
complement  factor  H  (CFH)  expression  from  RPE  cells,
implying that IFNγ has a potential role in AMD pathogenesis
[15]. In this study, we provide evidence that IFNγ promoted
human  VEGF  secretion  from  human  RPE  cells.
Unexpectedly,  IFNγ-induced  hVEGF  secretion  was  not
through the classic IFNγ Jak/Stat1 pathway, but through the
PI-3K/mTOR/p70-S6K-translational regulation pathway.
METHODS
Cell culture: ARPE-19 cells (ATCC, Manassas, VA) were
routinely cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS),
penicillin,  streptomycin  (100  U/ml  each),  and  2  mM  L-
glutamine  (Invitrogen,  Carlsbad,  CA).  Human  fetal  RPE
(hfRPE) cells were kindly provided by Section on Epithelial
and Retinal Physiology of National Eye Institute. hfRPE cells
were cultured in Minimum Essential Medium Alpha (MEM-
α)  modified  medium  with  additional  supplements,  as
described previously [16]. Only passage 1 was used. Both
primary hfRPE and an adult RPE cell line, ARPE-19, were
used to detect IFNγ-promoted VEGF mRNA expression by
real time PCR. In the subsequent experimental settings, only
ARPE-19 was used. The cells were cultured in the presence
or absence of 25 ng/ml IFNγ, 10 ng/ml TNFα, 50 ng/ml IL-6,
and 12.5 ng/ml transforming growth factor β1 (TGFβ1).
Real-time  polymerase  chain  reaction:  Total  RNA  was
extracted  from  confluent  monolayers  of  hfRPE  (P1)  and
ARPE-19 cells (RNeasy Kit; Qiagen, Valencia, CA). Total
RNA  (100  ng-1  µg)  was  reverse-transcribed  to  cDNA
(ReactionReadyTM  First  Strand  cDNA  Synthesis  Kit,
SABiosciences, Frederick, MD). RNA samples were tested
for VEGF gene expression by using the quantitative real time
PCR (RT–PCR) MasterMix from SABiosciences, following
their  RT–PCR  manual.  Real-time  PCR  was  performed  in
triplicate, using a 96-well format PCR array and an ABI 7500
real-time PCR unit (Applied Biosystems, Foster city, CA).
Primers  for  hVEGF-A,  Glyceraldehyde-3-phosphate
dehydrogenase  (GAPDH),  and  18S  rRNA  (rRNA)  were
purchased from SABiosciences and had been verified by the
provider. Human GAPDH and Human 18S rRNA were used
as internal standards. The results were expressed as the n-fold
expression of hVEGF, normalized on that of GAPDH and 18S
RNA.
Thiazolyl  blue  tetrazolium  bromide  assay:  Ten  thousand
ARPE-19 cells per well were seeded in a 96-well plate and
incubated overnight to allow the cells to attach to the plate.
Thiazolyl blue tetrazolium bromide (MTT) was added into the
media at the final concentration of 0.5 mg/ml for 4 h to allow
MTT to be metabolized. Media were dumped off, and cells
were resuspended in formazan (MTT metabolic product) in
200 µl dimethyl sulfoxide (DMSO). Optical density was read
at 540 nm and background was substracted at 670 nm.
Sodium  dodecyl  sulfate  PAGE  (SDS–PAGE)  and  western
blotting: A total of 1 million ARPE-19 cells were lysed in
100 μl lysis buffer (50 mM Tris-Cl, 1% Triton X-100, 100 mM
NaCl, 2 mM EDTA, 50 mM NaF, 50 mM glycerol-phosphate,
1  mM  NaVO4,  and  1×  protease  inhibitor  cocktail  [Roche
Molecular Biochemicals, Indianapolis, IN]). Samples were
prepared  by  adding  an  equal  amount  of  2×  SDS  protein
loading buffer. Then the cells were vortexed and boiled at
95 °C for 5 min to achieve complete cell lysis. Cell debris was
removed by centrifugation. Immunoblotting was performed
according to the standard protocols. Primary antibodies of
anti-phospho-protein  kinase  B  (Akt),  anti-phospho-Stat1,
anti-Stat1,  anti-phospho-p70  S6  kinase,  phosphor-S6
ribosomal  protein,  and  phospho-Eukaryotic  translation
initiation  factor  4E-binding  protein  1  (4E-BP1)  were
purchased from Cell Signaling Technology (Beverly, MA).
Anti-β-actin antibody was from Santa Cruz Biotechnology,
Inc.  (Santa  Cruz,  CA).  Anti–GAPDH  antibody  was  from
Abcam (Cambridge, MA).
SiRNA  transfection:  Stat1  SiRNA  (ON-TARGETplus
SMARTpool)  was  purchased  from  Thermo  Scientific
(Lafayette,  CO).  Akt  SiRNAs  were  from  Cell  Signaling
Technology). The delivery of SiRNA to ARPE-19 cells was
achieved  by  using  DharmaFECT  transfection  reagents
following  the  Thermo  Scientific  DharmaFECT  General
Transfection Protocol. After 48 h of transfection, the cells
were stimulated with or without IFNγ.
Measurement  of  hVEGF  secretion  from  cells:  Cell
supernatants  were  analyzed  for  VEGF  with  the  use  of
commercially available enzyme-linked immunosorbent assay
(ELISA)  kits  (R&D  Systems,  Minneapolis,  MN).  The
measurements  were  conducted  according  to  the
manufacturer's  instructions.  All  samples  were  assayed  in
triplicates and the mean of the values was calculated.
Statistical analysis: Analysis of hVEGF expression in cell
supernatants was performed using the independent Student's
t-test. In the figures, a single asterisk and a double asterisk
indicate  statistically  significant  at  p<0.05  and  p<0.01,
respectively.
RESULTS
IFNγ  promoted  VEGF  expression  of  RPE  cells:  Because
VEGF is one of the central regulators of vessel development,
we  were  interested  in  testing  whether  pro-inflammatory
cytokines could affect VEGF production and secretion from
retinal cells. We used both primary fRPE and an adult RPE
cell line, ARPE-19, to detect the effect of IFNγ on VEGF
mRNA expression. We first treated fRPE cells with IL-6,
IFNγ, TNFα, and TGFβ1 overnight. Cells were collected and
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185RNA was purified for real time PCR assay using GAPDH as
an internal standard. Compared to the control cells, IFNγ,
IL-6, and TGFβ increased VEGF mRNA expression 2.56,
1.71, and 1.81 fold, respectively (Figure 1A, experiment 1).
Another  set  of  data  showed  a  similar  trend  (Figure  1A,
experiment 2). We also used 18S rRNA as an internal standard
and found similar results. We then examined whether the same
effect was also observed in ARPE-19 cells. As shown in
Figure 1B, IFNγ started to induce VEGF expression at 6 h. At
24  h  after  treatment,  IFNγ  greatly  induced  VEGF  RNA
expression (p<0.01). Since we obtained similar results using
both  fRPE  and  ARPE-19  cells,  considering  that  cell
accessibility and adult RPE cells are more relevant to the
pathological  situation,  we  used  ARPE-19  cells  in  the
subsequent experimental settings. We next performed ELISA
experiments to measure hVEGF secretion of ARPE-19 cells
48 h after cytokine treatment. As shown in the dose-dependent
induction of hVEGF expression from ARPE-19 cells (Figure
1C), 1.0 ng/ml IFNγ started to induce hVEGF expression, with
the  highest  effect  at  25  ng/ml.  However,  the  anti-
proinflammatory  cytokine,  IL-10,  did  not  affect  hVEGF
expression in ARPE-19 cells. MTT assay was used to detect
cell number and viability after IFNγ treatment. As shown in
Figure 1D, IFNγ slightly reduced ARPE-19 cell number and
viability. We then compared the pro-inflammatory cytokines’
effect on VEGF expression using 25 ng/ml IFNγ, 10 ng/ml
TNFα, and 50 ng/ml IL-6. ARPE-19 cells were treated with
the above cytokines and a cocktail of these three cytokines.
Cell  supernatants  were  collected  after  48  h  and  used  for
ELISA. As shown in Figure 1E, IFNγ, IL-6, TNFα, and the
cytokine cocktail increased VEGF secretion 3.9, 1.22, 1.82,
and 5.6 fold, respectively, higher than the controls (p<0.01).
IFNγ had a more potent effect on VEGF secretion than did
IL-6  or  TNFα.  The  cytokine  cocktail  appeared  to
synergistically stimulate VEGF production from RPE cells.
Stat1  activation  is  not  involved  in  IFNγ-induced  VEGF
secretion: Jak/Stat1 is the classic pathway IFNγ going through
in signal transduction. We wanted to determine if this pathway
is involved in IFNγ-induced VEGF secretion. We directly
decreased  Stat1  phosphorylation  by  transfecting  SiRNA
oligos targeting Stat1 into ARPE-19 cells. As shown in Figure
2A, compared to mock transfection, RPE cells with SiRNA
of  Stat1  had  a  dramatically  lower  expression  of  Stat1
phosphorylation.  However,  IFNγ-induced  VEGF  secretion
showed  no  significant  change  between  Stat1  SiRNA
tansfected cells and control cells (Figure 2B).
mTOR/translational  pathway  is  involved  in  IFNγ-induced
VEGF secretion from RPE cells: We assessed whether the
mammalian  target  of  rapamycin  (mTOR)  pathway  was
activated by IFNγ by determining the phosphorylation state
of a series of downstream protein translation targets, such as
p70-S6K1, S6 ribosomal protein, and 4E-BP1. As shown in
Figure 3A, IFNγ dramatically increased the phosphorylation
of these proteins after 15, 30, and 60 min of stimulation (see
lanes 2, 4, and 6). Rapamycin greatly blocked the activation
of the mTOR pathway by IFNγ (see lanes 3, 5, and 7). The
role  of  mTOR  in  IFNγ-induced  VEGF  expression  was
evaluated. The administration of 10 nM rapamycin in the cell
culture, at the same time as adding IFNγ, decreased VEGF
mRNA expression (p<0.05, Figure 3B). Consistent with real-
time PCR data, the ELISA results also demonstrated that
IFNγ reduced VEGF secretion (p<0.01; comparing 2,181.5
pg/ml to 1,428.1 pg; Figure 3C). Rapamycin’s effect on the
classic Jak-Stat1 pathway after activation by IFNγ was also
tested. As shown in Figure 3D, rapamycin did not change
IFNγ-induced Stat1 phosphorylation.
PI3K/mTOR  translational  pathway  is  involved  in  IFNγ-
induced VEGF expression: Multiple signaling pathways are
activated during engagement of IFNγ with its receptor. Here,
we used the PI3K inhibitor, LY294002, to detect if PI3K
inhibition could affect IFNγ-induced activation of mTOR and
its downstream molecules. Western blot staining showed that
LY294002  completely  blocked  IFNγ-induced  akt
phosphorylation, confirming the inhibitory effect of PI-3K
(Figure  4A).  Furthermore,  LY294002  diminished  IFNγ-
dependent downstream activation of the mTOR and p70 S6K
pathways and the phosphorylation of 4E-BP1 (Figure 4A).
However,  LY294002  did  not  inhibit  IFNγ-induced  Stat1
tyrosine phosphorylation (Figure 4B). We then tested whether
PI-3K  activation  was  involved  in  IFNγ-induced  hVEGF
expression.  As  shown  in  Figure  4C,  LY294002  greatly
reduced hVEGF mRNA expression. The ELISA data (Figure
4D) also showed that LY294002 almost completely abrogated
IFNγ-induced  VEGF  secretion  from  RPE  cells  (p<0.01;
compare 923.2 pg/ml to 405.75 pg/ml. The control without
adding IFNγ was 335.1 pg/ml.) To further address the role akt
plays in IFNγ-induced VEGF expression, we knocked down
the akt expression by transfecting SiRNA, targeting akt into
ARPE-19  cells.  As  shown  in  Figure  4E,  akt  SiRNA
dramatically  decreased  akt  expression  compared  to  mock
transfection.  Consistent  with  Figure  4C,D,  akt  SiRNA
transfection greatly reduced the expression of hVEGF from
ARPE-19 cells after IFNγ treatment (Figure 4F).
DISCUSSION
In the present study, we demonstrate that IFNγ induces VEGF
secretion in RPE cells, and that this effect is dependent on the
PI-3K/mTOR pathway. RPE is a single layer of epithelial cells
in the back of the eye, acting as the outer blood-retinal barrier.
Dysregulation  of  RPE  has  been  implicated  in  AMD
pathogenesis  and  ocular  inflammation  [17–20].  IFNγ  is  a
crucial modulator of the immune system. It is produced by
specific subsets of T lymphocytes and NK cells, and plays an
important role in ocular pathogenesis [21,22]. IFNγ has a
pleiotropic effect in the ocular environment. Not only is it
involved in local inflammatory response, but it also magnifies
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186Figure  1.  IFNγ-promoted  vascular
endothelial  growth  factor  (VEGF)
expression of RPE cells. A: fRPE cells
were  seeded  in  a  96-well  plate  and
treated  with  IFNγ,  IL-6,  TNFα,  and
TGFβ1 overnight. In each experiment,
each  treatment  was  performed  in
triplicate. After 24 h of culture, cells
were  collected  and  pooled  for  RNA
purification. Real-time PCR assay was
performed,  and  the  results  were
expressed as the n-fold expression of
hVEGF normalized on that of GAPDH
or  18S  rRNA.  The  asterisk  indicates
statistical  significance  (p<0.05)
compared  to  the  non-treated  control
group. B: ARPE-19 cells were cultured
with IFNγ for 6 h and 24 h. Cells were
collected, and the RNA was purified for
real-time PCR assay. The results were
expressed as the n-fold expression of
hVEGF normalized on that of GAPDH
or 18S rRNA. The values are expressed
as the average+SEM of triplicates for
each  treatment.  The  results  were
representative  data  from  two  separate
experiments.  The  asterisk  and  the
double  asterisk  indicate  statistical
significance  (p<0.05  and  p<0.01,
respectively)  compared  to  the  non-
treated control group. C: ARPE-19 cells
were cultured with 0, 0.1, 1.0, 10.0, and
25  ng/ml  IFNγ,  as  well  as  10  ng/ml
IL-10, for 48 h. Cell supernatants were
collected and used for ELISA analysis.
The  y-axis  represents  hVEGF
concentration  (pg/ml).  D:  ARPE-19
cells were cultured with or without 25
ng/ml IFNγ for 48 h. MTT assay was
used to detect cell viability. E: ARPE-19
cells  were  treated  with  IL-6,  IFNγ,
TNFα,  and  a  cocktail  of  these  three
cytokines  for  48  h.  Cell  supernatants
were  collected  and  used  for  ELISA
analysis. The y-axis represents hVEGF
concentration  (pg/ml).  The  double
asterisk indicates statistical significance
(p<0.01) compared to the control group.
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187this response in the outer retina. It upregulates the expression
of MHC class II, ICAM-1, IL-6, IL-8, and MCP-1 in RPE
cells, which collectively lead to alteration of RPE antigenic
properties, and activation and recruitment of leukocytes in the
retina,  further  contributing  to  ocular  immunopathological
processes  [23–26].  Moreover,  IFNγ  is  also  reported  to
increase the expression of reactive oxygen species, which has
been  implicated  in  ocular  inflammation  and  retinal
degeneration  [27].  The  data  from  IFNγ  transgenic  animal
models also support this notion. Geiger et al. found IFNγ
transgenic mice developed intraocular disease, manifested as
inflammatory-cell  infiltration  and  photoreceptor  loss  [28].
Egwuagu and his associates also reported IFNγ transgenic
mice had higher MHC class II expression in the eye, and the
mice developed microphthalmia and microphakia [29]. The
ectopic expression of IFNγ in photoreceptors disturbed the
intraocular  immune  privilege  in  transgenic  mice  and
prevented  the  induction  of  anterior  chamber-associated
immune deviation [30]. In IFNγ-transgenic rats, it has been
reported  that  IFNγ  accelerated  the  onset  of  experimental
autoimmune  uveitis  (EAU)  [31].  Interestingly,  IFNγ  also
plays a protective role in regulating ocular immune response.
Kim et al. [15] reported that IFNγ upregulated human CFH
expression. CFH has been implicated in AMD pathogenesis
and is an important component of downregulatory intraocular
environment (DIE) [32]. Li et al. [33] found that application
of IFNγ to the anterior surface of the rat eye could remove
extra fluid in the subretinal region. This protective role in
regulating retinal hydration may have implications for ocular
pathogenesis,  and  more  specifically,  for  macular  edema-
associated AMD and uveitis. In the mouse EAU models, it has
been  shown  that  IFNγ  has  a  protective  effect  on  EAU
development, which contradicts the effects observed from
human and rat EAU models [34]. Overall, the mechanisms of
IFNγ function in different species need to be further explored.
Earlier  reports  emphasized  that  IFNγ  is  an  anti-
angiogenic cytokine. It inhibits the growth of endothelial cells
(ECs)  and  induces  the  apoptosis  of  ECs  [6].  In  addition,
treatment of ECs with IFNγ results in a decreased expression
of the platelet EC-adhesion molecule (PECAM)-1, which is
constitutively  expressed  by  the  vascular  endothelium  and
concentrates at intercellular junctions [8,35]. The regulation
of  PECAM-1  expression  by  IFNγ  is  thought  to  affect
leukocyte  trafficking,  angiogenesis,  and  vascular
permeability.  Moreover,  IFNγ  acts  on  ECs  by  inducing
IFNγ-inducible protein 10 (IP-10) expression, which inhibits
angiogenesis [36]. The proposed inhibitory effect of IFNγ on
angiogenesis is not solely due to its direct activity on ECs.
IFNγ differentially regulates IP-10 and IL-8 expression in
RPE cells. Along with IL-1β and TNFα, IFNγ induced at least
ten-fold higher IP-10 than IL-8, suggesting its direct anti-
angiogenic effect [37]. Hooks and associates showed that
IFNγ acts as an anti-angiogenic cytokine in the human cornea
by  inhibiting  VEGFA  and  enhancing  soluble  VEGF-R1
secretion in human corneal stromal fibroblast cells [7]. Tumor
cells  respond  to  IFNγ  by  suppressing  the  expression  of
MMP-9 and MMP-2 genes, which are involved in the invasion
and angiogenesis process of malignant tumors [38,39]. Betty
et al. showed the inhibition of tumor angiogenesis by tumor-
infiltrating CD4+ T cells to be IFNγ dependent [40]. Ray et
al.  reported  that  IFNγ  suppresses  VEGFA  expression  in
monocyte-macrophages  through  translational  silencing,  by
inducing  the  IFNγ-activated  inhibitor  of  translation  [41].
Furthermore,  IFNγ  has  been  shown  to  downregulate  the
expression  of  granulocyte-macrophage  colony  stimulating
factor [42]. That and macrophage colony stimulating factor
Figure 2. Stat1 activation not involved in IFNγ-induced VEGF secretion. A: ARPE-19 cells were transfected with SiRNA oligos targeting
Stat1. After 3 days, cells were cultured with or without IFNγ for 30 min. Cells were then collected and processed for western blot analysis for
p-Stat1 expression. The same blot was also stained with anti-β-actin antibody for loading control purposes. B: ARPE-19 cells were mock-
transfected or transfected with SiRNA of Stat1. Two days later, cells were treated with or without IFNγ for 48 h. Cell supernatants were
collected and used for ELISA analysis. The y-axis represents VEGF concentration (pg/ml). The values are expressed as the average+SEM of
triplicates for each treatment. The double asterisk indicates statistical significance (p<0.01) compared to the IFNγ group.
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188have been reported to be ideal targets for treating neovascular
diseases and cancer [43,44].
In addition to its anti-angiogenic effect, there are also
observations  supporting  its  pro-angiogenic  effects.  An
example  is  IFNγ’s  reported  angiogenic  effects  from
enhancing the secretion of VEGF from human keratinocytes
[45]. Shi et al. treated fRPE cells with IFNγ, IL-1β, and a
TNFα cytokine cocktail. They found that a significant amount
of  cytokines  and  chemokines  were  upregulated,  and  that
angiogenic  cytokines  were  secreted  at  a  greater  rate  than
angiostatic cytokines [46]. Here, we are more focused on
IFNγ’s effect on human RPE, because of the RPE’s central
role in macular pathology involving the posterior pole. We
therefore used human RPE cells as a model. For the first time,
we  have  shown  that  although  IFNγ  slightly  decreased
ARPE-19 cell growth (Figure 1D), IFNγ induced VEGFA
expression in ARPE-19 cells (Figure 1B,C). Compared to
IL-6,  TNFα,  and  TGFβ,  IFNγ  had  a  more  robust  VEGF-
promoting effect at both the RNA and protein levels (Figure
1A,E),  indicating  that  IFNγ  is  a  versatile  mediator  in
angiogenesis dysregulation associated with macular ocular
pathology involving the back of the eye.
The anti-proliferative, proapoptotic effects of IFNγ have
been  largely  attributed  to  the  activation  of  the  Jak/Stat1
signaling pathway [47–49]. However, several reports indicate
that IFNγ activation of the Jak/Stat pathway is not sufficient
to account for all the biologic actions of IFNγ [50–52]. Beyond
the Jak/Stat1 pathway, IFNγ can also activate the MAPK and
PI-3K/mTOR  pathways  [9].  However,  the  role  of  these
pathways  in  IFNγ-induced  biologic  effects  has  not  been
clearly defined. In this study, we provide evidence that the
PI-3K/Akt/mTOR/p70 S6 kinase pathway is important for
IFNγ-induced VEGF expression in human RPE cells. The
PI3K and mTOR inhibitors, along with Akt SiRNA, greatly
decreased IFNγ-induced hVEGF secretion from RPE cells
(Figure 3B,C and Figure 4C,D,F). On the other hand, neither
inhibitor  affected  IFNγ-induced  Stat1  phophorylation/
activation (Figure 3D and Figure 4B). Moreover, the IFNγ-
induced  hVEGF  expression  was  not  affected  by  SiRNA
targeted to Stat1 (Figure 2B), implying that the classic Jak/
Stat1  pathway  of  IFNγ  is  not  involved  in  this  VEGF-
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Figure 3. The mTOR/translational pathway was involved in IFNγ-induced VEGF secretion from RPE cells. A: ARPE-19 cells were cultured
with or without IFNγ in the presence or absence of rapamycin for 15, 30, and 60 min. Cells were collected and processed for western blot
analysis using anti-p-p70 S6 kinase, anti-p-S6 ribosomal protein, anti-p-4E-BP1, p-akt, and GAPDH antibodies. B: ARPE-19 cells were
cultured with or without IFNγ/rapamycin for 24 h. Cells were collected for RNA purification. Real-time PCR assay was performed and the
results were expressed as the n-fold expression of hVEGF normalized on that of GAPDH or 18S rRNA. C: ARPE-19 cells were cultured with
or without IFNγ/rapamycin for 48 h. Cell supernatants were collected and used for ELISA analysis. The values are expressed as the average
+SEM of triplicates of each treatment. The results were representative data from three separate experiments. The double asterisk indicates
statistical significance (p<0.01) compared to the IFNγ group. D: ARPE-19 cells were cultured with or without IFNγ in the presence or absence
of rapamycin for 15, 30, and 60 min. Cells were collected and processed for western blot analysis using anti-p-Stat1, Stat1, and GAPDH
antibodies. The results were representative data from two separate experiments.promoting effect. The precise mechanisms that determine how
the PI-3K/Akt/mTOR/p70 S6 kinase pathway affects VEGF
expression remain unclear and need to be further explored.
We  believe  these  observations  have  direct  clinical
implications. Even though the exact mechanisms leading to
AMD  remain  obscure,  early  reports  in  the  1980s  already
suggested  immune  system  involvement  [53,54].  Recently,
several genetic associations in humans [55] further implicate
immune-driven  mechanisms  in  AMD.  mTOR  is  a  crucial
molecule in mediating inflammation-induced angiogenesis.
In addition to IFNγ, which has been shown here to affect the
pathway,  other  proangiogenic  factors,  including  TNFα,
IL-1β, IL-6, IL-8, basic fibroblast factor (bFGF), and VEGF,
are  dependent  on  the  mTOR/translational  pathway  to
contribute to the overall angiogenic process [56]. In line with
this notion, an mTOR inhibitor, rapamycin, appears to be a
suitable  option  to  treat  CNV  that  is  secondary  to  any
pathologic process involving the RPE, including AMD. In
addition, rapamycin is also an immunosuppressant. It inhibits
T-lymphocyte activation and proliferation, in response to both
antigenic and cytokine stimulation [10]. The dual effects of
this agent may be useful in treating the inflammatorily driven
CNV. We are currently evaluating the use of rapamycin in
treating  AMD  patients  with  CNV.  The  data  suggest  that
rapamycin appears to affect the clinical course of AMD [data
not shown]. The availabilities of IFNγ transgenic or knockout
animal  models  may  also  help  to  elucidate  the  effect  of
rapamycin  on  ocular  neovascularization.  While  we  have
emphasized  the  important  role  the  mTOR/translational
pathway plays in IFNγ-induced VEGF expression, we cannot
exclude the possibility of other signaling pathways that are
also  important  for  this  process.  Kaur  et  al.  [50]  recently
showed  that  PI-3K  plays  a  dual  regulatory  role  in  IFNγ
signaling  by  controlling  IFNγ-dependent  transcriptional
regulation  of  IFN-sensitive  genes,  and  by  simultaneously
regulating the subsequent initiation of mRNA translation for
such  genes.  Consistent  with  their  results,  we  found  that
IFNγ could promote VEGF mRNA expression, as well as
protein secretion (Figure 1A,D).
Our findings provide further mechanistic insight into the
pathways leading to CNV in disorders in which, like AMD,
perturbation  of  RPE  plays  an  integral  role  in  disease
pathogenesis. Our investigation’s elucidation of molecular
signaling in IFNγ-induced VEGF expression provides further
justification  for  therapeutic  interventions  to  be  carefully
applied in the clinical setting.
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Figure 4. The angiogenic effect of IFNγ was through the PI-3K/mTOR translational pathway. A: ARPE-19 cells were cultured with or without
IFNγ in the presence or absence of LY294002 for 15, 30, and 60 min. Cells were collected and processed for western blot analysis using anti-
p-p70 S6 kinase, anti-p-S6 ribosomal protein, anti-p-4E-BP1, p-akt, and GAPDH antibodies. B: ARPE-19 cells were cultured with or without
IFNγ in the presence or absence of LY294002 for 15, 30, and 60 min. Cells were collected and processed for western blot analysis using anti-
p-akt, anti-p-Stat1, and GAPDH antibodies. The results were representative data from two separate experiments. C: ARPE-19 cells were
cultured with or without IFNγ/LY294002 for 24 h. Cells were collected for RNA purification. Real-time PCR assay was performed, and the
results were expressed as the n-fold expression of hVEGF normalized on that of GAPDH or 18S rRNA. D: ARPE-19 cells were cultured with
or without IFNγ/PI-3K inhibitor LY294002 for 48 h. Cell supernatants were collected and used for ELISA analysis. The y-axis represents
VEGF concentration (pg/ml). The values are expressed as the average±SEM of triplicates of each treatment. The double asterisk indicates
statistical significance (p<0.01) compared to the IFNγ group. E: ARPE-19 cells were mock-transfected or transfected with SiRNA of akt.
After 2 days, cells were then collected and processed for western blot analysis for akt expression. The same blot was also stained with GAPDH
antibody as a loading control. The results were representative data from two separate experiments. F: ARPE-19 cells were mock-transfected
or transfected with SiRNA of akt. Two days later, cells were treated with or without IFNγ for 48 h. Cell supernatants were collected and used
for ELISA analysis. The y-axis represents VEGF concentration (pg/ml). The values are expressed as the average±SEM of triplicates of each
treatment. The double asterisk indicates statistical significance (p<0.01) compared to the IFNγ group.ACKNOWLEDGMENTS
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